The murine leukemia virus envelope protein is synthesized as a precursor molecule, Pr85env, which is proteolytically cleaved at an arginine residue to produce two mature envelope proteins, gp7O and p15(E). The results presented here indicate that mutation to lysine of the arginine found at the envelope precursor cleavage site results in a precursor which is cleaved with an efficiency at least 10-fold lower than the efficiency with which the wild-type protein is cleaved. This mutation has been used to investigate the requirement for envelope protein processing in various aspects of retroviral infection. Viruses produced by cells transfected with mutant proviral clones are approximately 10-fold less infectious than wild-type viruses. Mutant viruses are incapable of inducing XC cell syncytium formation and are 100-fold less efficient than wild-type viruses at rendering cells resistant to superinfection. Envelope glycoproteins bearing the lysine mutation are found in reduced amounts on the surface of infected cells, and as a result mutant virions contain significantly less envelope protein than do wild-type virions. The phenotypic effects of the processing mutation described here are most likely the result of this paucity of envelope glycoproteins in virions carrying the mutation.
The envelope glycoproteins of a number of viruses are synthesized as polyprotein precursors that must be proteolytically cleaved for the virus to be infectious and for virus-induced membrane fusion activity to be exhibited. Examples of such glycoproteins include hemagglutinin of influenza virus (10) , F of Sendai virus (5), E2 of mouse hepatitis virus (4), gp62 of Sindbis and Semliki Forest viruses (19) , and F of respiratory syncytial virus (14) . This posttranslational cleavage is currently thought to be performed by trypsin or trypsinlike enzymes. Inspection of the amino acid sequences of these viruses reveals a conserved arginine residue at the cleavage site.
Retroviral envelope proteins, like those of other enveloped viruses, are synthesized as polyproteins which are proteolytically processed, after removal of a leader peptide, to the two mature envelope proteins: the larger glycosylated external receptor-binding protein and the smaller transmembrane anchor protein. The two murine leukemia virus (MuLV) envelope proteins have been termed, on the basis of apparent molecular weights, gp70 and p15(E) and are derived from the glycosylated precursor Pr85env (22) . The amino acid sequence at the envelope precursor cleavage site, Lys/Arg-X-Lys/Arg-Arg, is highly conserved among retroviruses (24) . The cleavage is made on the carboxy side of the terminal arginine by an unknown cellular enzyme; by analogy with other enveloped viruses, this enzyme may be trypsin or a trypsinlike enzyme. An additional late cleavage occurs that produces p12(E) and p2(E) from p15(E) (22) . This cleavage is thought to be performed by the virally encoded gag protease (20). It is not known whether either cleavage is necessary for retroviral replication.
Endogenous ecotropic MuLVs are a well-characterized class of retrovirus found in the germ lines of a variety of inbred mouse strains. Two such mouse strains, AKR and BALB/c, harbor proviruses which are approximately 99.5% homologous at the nucleotide level (7) . Despite this high degree of sequence conservation, these two viruses differ * Corresponding author.
phenotypically in several respects. The AKR endogenous ecotropic provirus (AKV) is 10-to 100-fold more infectious than the BALB/c virus (7), and, like most ecotropic MuLVs, AKV induces XC cell syncytium formation in the assay developed by Rowe et al. (18) , whereas the BALB/c virus does not (7) . Comparison of the DNA sequences of these two viruses indicates that a mutation is present in the BALB/c provirus that changes the terminal amino acid of the envelope protein cleavage sequence from Arg to Lys (7) . Previous work in this laboratory indicated that this mutation may be responsible for the inability of the BALB/c endogenous virus to induce XC cell syncytia and led to the speculation that this phenotype is caused by inefficient cleavage of the envelope precursor (7) .
In this report, we present evidence that the Arg-to-Lys mutation at the site of envelope precursor processing does lead to a dramatic reduction in the efficiency of envelope protein precursor processing and transport. This defect causes the mutant virus to be unable to induce XC cell fusion, to be less infectious, and to be less effective at establishing interference than the wild-type virus.
MATERIALS AND METHODS
DNA cloning and sequencing. Standard DNA cloning techniques were used in the construction of pEF38 (13) . Restriction enzymes were purchased from New England BioLabs, Inc., Beverly, Mass.; digests were done as recommended by the supplier. Ligations were done with T4 DNA ligase (New England BioLabs), and the DH-5 strain of Escherichia coli was transformed by the method of Hanahan (2) . Transformed colonies were screened by alkaline lysis and restriction enzyme analysis. M13 DNA sequencing was done as previously described (7) . Details concerning the construction of pEF38 will be provided upon request.
Transfections and virus assays. NIH 3T3 cells were transfected by the calcium phosphate precipitation technique first described by Graham and Van der Eb (1) and modified by Hopkins et al. (6) . Syncytium induction in the XC cell line was measured by the method of Rowe et al. (18) .
Immunofluorescence assays were done as described by Hartley et al. (3) . Reverse transcriptase assays were done essentially as described by Rapp and Nowinski (15 Kessler (9) . For gp7O and gag protein immunoprecipitations, polyclonal antibodies were mixed with the labeled precleared cell lysates and collected with a 10% solution of S. aureus that had been boiled in 2-mercaptoethanol and washed in NET (0.15 M NaCl, 5 mM EDTA, 50 mM Tris) containing 0.5% Nonidet P-40 (Sigma Chemical Co., St. Louis, Mo.) (17) . After incubation on ice, the samples were pelleted, washed in phospholysis buffer-1% Trasylol, and solubilized by being boiled in a sample buffer containing 10% glycerol, 5% 2-mercaptoethanol, 3% SDS, and 0.5x Tris. The samples were subsequently subjected to SDS-polyacrylamide gel electrophoresis and fluorographed by using En3Hance (New England Nuclear Corp., Boston, Mass.) and X-Omat AR film (Eastman Kodak Co., Rochester, N.Y.). To reduce the background caused by nonspecific precipitation of nonviral proteins, the following modification of the above protocol was introduced for the immunoprecipitation of [35S]methionine-and 125I-labeled cell lysates. After being washed with phospholysis buffer-1% Trasylol, the samples were suspended in phospholysis buffer-1% Trasylol, boiled, centrifuged at 10,000 x g, and reprecipitated. NCI 79S-00834 anti-gp7O and NCI 79S-450 anti-gag antisera were used. p15(E) was precipitated by first combining 2-mercaptoethanol-boiled S. aureus with goat anti-rat immunoglobulin G, incubating this mixture overnight at 4°C, and adding cell lysate and anti-plS(E) (Hy65; obtained from M. Cloyd, Duke University) monoclonal supernatant.
Labeling, harvesting, and immunoprecipitation of virions. Virus-producing NIH 3T3 cells were labeled for 12 h as described above, and the medium was removed and centrifuged at low speed to pellet unattached cells and cell debris. The supernatant from this centrifugation was centrifuged at 35,000 rpm in an SW7OTi rotor (Beckman Instruments, Inc., Fullerton, Calif.), and the virus pellet was solubilized in phospholysis buffer containing 1% Trasylol, precleared with normal goat serum and a 10% solution of S. aureus, and immunoprecipitated with anti-gp7O antiserum as described above.
RESULTS
Envelope glycoprotein processing in the BALB/c and AKR ecotropic MuLVs. The BALB/c ecotropic provirus bears a mutation that changes the arginine found at the site of the wild-type AKV envelope glycoprotein cleavage to lysine. To compare the envelope protein-processing characteristics of these two viruses, we transfected NIH 3T3 cells with the infectious AKV proviral clone p623 (12) and the infectious BALB/c proviral clone p7D (7). At 2 weeks posttransfection,
[35S]methionine-labeled cell lysates were prepared and immunoprecipitated with anti-gp7O serum. Untransfected NIH 3T3 cells were labeled as a control. Pr85env and gp7O were present in immunoprecipitates of p623-transfected cells, whereas only the precursor was detected in immunoprecipitates of p7D-transfected cells. No viral proteins were detected in immunoprecipitates of NIH 3T3 cells (Fig. 1, lanes  1 to 3) . The mature envelope protein p15(E) was observed in p623-transfected but not in p7D-transfected or untransfected lysates (data not shown). These data indicated that proteolytic processing of the p7D envelope precursor to the mature envelope proteins was defective.
Transfer of the BALB/c virus processing mutation to AKV. To determine whether the amino acid change at the site of Pr85env, cleavage is responsible for the envelope glycoprotein-processing defect, we constructed a plasmid, pEF38, whose proviral DNA is identical to that of p623 except for the single nucleotide change that encodes the lysine at the BALB/c virus envelope glycoprotein-processing site. Essentially, a p623 fragment spanning the processing junction was replaced with the corresponding region from p7D. This region differed between the two proviral sequences by only one nucleotide. To confirm that the desired change had been made, the region of the plasmid encoding the gp7O-pl5(E) junction was sequenced, and it was determined that a lysine codon was present at the site of pEF38 glycoprotein cleavage (data not shown). After its construction, pEF38 was used to transfect NIH 3T3 cells in parallel with p623. The infectivities of the two plasmids were determined by enumerating the number of fluorescent antibody-positive foci and XC plaques per microgram of proviral DNA. The infectivities of the pEF38-derived virus vEF38 and of AKV were determined with harvests from cells 7 days posttransfection. A reverse transcriptase assay was done to determine the relative amounts of virus in the AKV-and vEF38-infected cell supernatants. The data obtained from these experiments indicated that vEF38 is at least 10-fold less infectious than AKV and is unable to induce fusion of XC cells (Table 1) .
vEF38-and AKV-infected cells were examined in parallel for their sensitivity to focus formation by pseudotype pools of Harvey murine sarcoma virus enveloped with amphotropic or ecotropic proteins (Table 2 ). These data demonstrate that vEF38 is roughly 100-fold less effective than AKV at establishing viral interference to ecotropic MuLV. vEF38 and AKV do not significantly interfere with infection by Harvey murine sarcoma virus pseudotyped with amphotropic envelopes.
Intracellular expression of EF38 envelope proteins. To test whether the single nucleotide mutation in pEF38 has an effect on envelope protein processing, we immunoprecipitated r35S]methionine-labeled lysates prepared from cells 7 days after transfection with pEF38 or p623 (Fig. 1A) . Both the envelope protein precursor Pr85env and the mature gp7O protein were present in p623-transfected cells (lane 2), whereas only the precursor was detected in p7D-transfected cells (lane 3) . In immunoprecipitates of pEF38-transfected cells (lane 4), only the precursor protein was detected. A longer exposure of this gel (Fig. 1B) indicated the presence in the EF38 lanes (lanes 4 and 5) of a protein that migrated to around 100 kilodaltons. The suspected identity of this pro- tein, which we refer to as PrlOOeni', will be discussed later. The data shown in Fig. 1A and 1B clearly indicate that the Arg-to-Lys mutation inhibits the proteolytic processing of the envelope protein precursor.
To determine the limit of our ability to detect gp7O in the immunoprecipitations shown in Fig. 1 (Fig. 2) . One-half of the immunoprecipitated sample was digested with endo-H, an enzyme that cleaves the highmannose oligosaccharide side chains added in the endoplasmic reticulum (8) . To quantitate the amounts of viral proteins in this experiment, bands were cut from the gel and measured by liquid scintillation counting. In AKV-infected cells, a small amount of gp7O was present after the 1-h labeling period, and as the chase time increased so did the amount of gp7O relative to Pr85env'. In vEF38-transfected cells, a substantial amount of PrlOOenv appeared during the labeling period and then dropped off below our level of detection within 2 h. gp7O was not detected in these cells. In both AKV-and vEF38-infected cells, the total amount of envelope protein decreased with time as it was shed from cells in virions. The apparent molecular sizes of gp7O and PrlOOenv' were not decreased by endo-H, indicating that they contained endo-H-resistant complex sugar side chains. The apparent molecular size of Pr85ent' was decreased to 65 to 70 kilodaltons after endo-H digestion, indicating that it contained endo-H-sensitive high-mannose sugar side chains. These results suggest that since PrlOOenv contains endo-H- 6, and 9) . Cell lysates were immunoprecipitated with anti-gp70 antiserum. The undefined arrow indicates the position of PrlOOenv. Lanes: 1 to 3, NIH 3T3 cells; 4 to 6, AKV-infected immunoprecipitates; 7 to 9, vEF38-infected immunoprecipitates. K, Kilodaltons. (8) . Lysates from these sugar-labeled cells were prepared and immunoprecipitated with anti-gp7O antiserum (Fig. 3) . In AKV-infected cells, both Pr85env and gp7O were labeled with [3H]mannose and [3H]glucosamine (lanes 4 and 5), whereas only gp7O was labeled with [3HJfu-cose (lane 6). This result suggests that the AKV envelope glycoprotein precursor is proteolytically cleaved before it arrives in the compartment of the Golgi apparatus in which fucose addition occurs. In vEF38-infected cells, the precursor was labeled with [3H]mannose and [3H]glucosamine (lanes 7 and 8) but was not labeled with [3H]fucose (lane 9). PrlOOenv was labeled with all three sugars, consistent with the notion that this species is an uncleaved envelope glycoprotein containing complex sugar side chains. gp7O was not detected in any of the vEF38 immunoprecipitates.
Display of vEF38 envelope proteins on viral envelopes and cellular membranes. To examine virion envelope glycoproteins, [35S]methionine-labeled viruses were solubilized and immunoprecipitated with anti-gp7O and anti-gag antisera (Fig. 4) . The major gag proteins detected in both vEF38 and AKV immunoprecipitates were p30 and the gag precursor Pr65. p15 and plO contain no methionine residues and were therefore not labeled. The envelope proteins in AKV immu- 3, and, 5 To determine the relative amounts of envelope glycoprotein on cell membranes, AKV-and vEF38-infected cells were surface labeled with 125I and immunoprecipitated with anti-gp7O antibody (Fig. 5) . The levels of PrlOOenv, and gp7O on the surfaces of vEF38-infected cells were below the limits of detection in this assay, whereas gp7O was clearly present on AKV-infected cells. These results indicate that AKV-infected cells contain significantly more cell surface envelope protein than do vEF38-infected cells.
DISCUSSION
The endogenous ecotropic virus of the BALB/c inbred strain of mouse is unable to induce the fusion of XC cells in culture and is less infectious and less effective at establishing superinfection interference than is AKV, the endogenous ecotropic virus of the AKR inbred strain of mice. A mutation is present in the BALB/c virus that converts the arginine found at the site of envelope glycoprotein cleavage to lysine. The transfer of this single nucleotide mutation to AKV allows us to examine the effects of this mutation on the biology of the virus and on the kinetics of envelope glycoprotein processing, glycosylation, and transport. (23) .
In light of recent reports indicating that T-cell fusion induced by the envelope glycoprotein of the acquired immune deficiency syndrome virus (human immunodeficiency virus) may be a major contributor to the pathogenicity of this virus (11, 21) , we believe that fusion-abrogating mutations such as the one reported here are of interest not only in exploring the effects of these mutations during retroviral infection and envelope protein-induced cell fusion but also in studying the role of envelope proteins in disease processes.
